Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
September 07, 2022 16:05 ET
|
Erasca, Inc.
23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601 ...
Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
August 24, 2022 08:00 ET
|
Erasca, Inc.
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future...
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
August 23, 2022 08:00 ET
|
Erasca, Inc.
Initial focus of five-year collaboration will be on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which together comprise Erasca’s first MAPKlamp combination ...
Erasca Reports Second Quarter 2022 Financial Results and Business Updates
August 11, 2022 16:05 ET
|
Erasca, Inc.
Initial Phase 1b monotherapy data for ERAS-007 in HERKULES-1 and first-in-human Phase 1 monotherapy data for ERAS-601 in FLAGSHP-1 expected in H2 2022 IND filing for CNS-penetrant KRAS G12C inhibitor...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
July 18, 2022 08:00 ET
|
Erasca, Inc.
ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with Lilly and...
Erasca to Present at the 2022 Jefferies Healthcare Conference
June 03, 2022 09:00 ET
|
Erasca, Inc.
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers
June 02, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments
May 25, 2022 08:00 ET
|
Erasca, Inc.
Shannon Morris, M.D., Ph.D., appointed as Senior Vice President of Clinical Development Amy Grekowicz Parker appointed as Vice President of Clinical Operations John Lo, Ph.D., appointed as Senior...
Erasca Reports First Quarter 2022 Financial Results and Business Updates
May 12, 2022 16:01 ET
|
Erasca, Inc.
Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs Initial Phase 1b monotherapy data for ERAS-007 and Phase 1...
Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
May 03, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...